Can low vitamin D levels contribute to depression or low mood?

People with depression are more likely to have low vitamin D levels. That alone does not mean the deficiency causes their symptoms. Where a deficiency exists, taking vitamin D might ease depressive symptoms, although the studies on this point reach different conclusions. In people whose levels are already adequate, an added benefit for mood has not been convincingly shown.

Vitamin D influences several processes in the brain, which is why researchers are looking into a possible link with depression. The biological mechanisms on their own, however, show neither that a low level triggers depression nor that vitamin D can treat it.

What vitamin D does in the brain

Vitamin D is the precursor of a steroid hormone. When ultraviolet B radiation (UVB for short) reaches the skin, the skin makes cholecalciferol from 7-dehydrocholesterol. Enzymes in the liver and kidneys then modify this molecule in several steps. These steps, called hydroxylations, eventually produce the active hormone form, calcitriol. Calcitriol binds to vitamin D receptors throughout the body, including receptors in brain regions that regulate mood, thinking and stress responses.

These receptors are found in the prefrontal cortex, the hippocampus, the hypothalamus and the substantia nigra. Among other things, these regions are involved in planning and impulse control, consolidating memories, the day-night rhythm and dopamine production. When vitamin D binds to its receptors, it can influence how certain genes are read. Those genes play a part in making neurotransmitters, protecting nerve cells and regulating inflammation.

One mechanism under study involves tryptophan hydroxylase 2 (TPH2). This enzyme controls a step that helps set the pace of serotonin production in the brain. Vitamin D can influence how the enzyme is regulated, so researchers are investigating whether a poor vitamin D supply could impair serotonin production and, with it, mood regulation. Vitamin D plays a different role here from tryptophan, the amino acid we get from food: tryptophan supplies a raw material for serotonin, while vitamin D might influence how that raw material is processed. A low vitamin D level does not mean this conversion necessarily grinds to a halt, though.

What clinical studies show about vitamin D and depression

A 2019 meta-analysis that pooled results from 61 observational studies reported that depression was statistically significantly more common in people with vitamin D deficiency than in people with adequate levels. The association held after accounting for physical activity, sun exposure and mental health at baseline. The full reference for this analysis is missing. Observational data also cannot prove cause and effect. Still, the fact that similar associations appeared in several groups, and that biological explanations are plausible, gives reason to keep investigating whether vitamin D plays a role.

Randomized controlled trials paint a less consistent picture. In these studies, chance decides who receives vitamin D and who receives a comparison treatment. A 2014 meta-analysis reported that depressive symptoms improved more with vitamin D than with placebo, a dummy pill. The effect was described as moderate and clinically relevant, especially in groups with 25-OH vitamin D levels below 20 ng/mL. 25-OH vitamin D is the storage form usually measured in blood. The full reference for this meta-analysis is missing as well. Studies in participants who already had adequate levels showed little or no benefit. These differences fit with a possible benefit from correcting a deficiency; whether baseline levels alone explain the diverging results remains an open question.

The VITAL-DEP trial, published in 2020, tested in more than 18,000 adults whether 2,000 IU of vitamin D3 a day for five years could prevent depression. IU stands for international units. There were neither significantly fewer new cases of depression nor meaningful improvements in mood scores. At the start, the average 25-OH vitamin D level was 30 ng/mL, above the deficiency cutoff used in this article. So the trial mostly studied extra supplementation in people with adequate levels. It was not specifically designed to treat an existing deficiency. VITAL-DEP, randomized trial from 2020.

The 2023 meta-analysis on vitamin D supplementation in older adults is a separate analysis. Its findings should be kept apart from the VITAL-DEP results report.

A 2018 study in women with type 2 diabetes and depression is described as showing a significant improvement in depressive symptoms compared with placebo after 50,000 IU per week for eight weeks. The effect is said to have been strongest at baseline levels below 20 ng/mL. This high dose refers to a study treatment and is not a recommendation for self-medication. The study cannot be clearly identified from the reference list, however. The trial by Jorde and Kubiak from 2018 that is listed there is titled “No improvement in depressive symptoms by vitamin D supplementation: results from a randomised controlled trial” and so does not match the improvement described.

The differences between studies suggest that baseline vitamin D levels should be taken into account when interpreting the results. That does not establish a reliable benefit for everyone with a deficiency, nor a clear relationship between dose and change in depressive symptoms.

How vitamin D affects serotonin, dopamine and the stress response

Serotonin production and distribution

According to one proposed mechanism, vitamin D regulates TPH2 in the brain while inhibiting TPH1, an enzyme involved in making serotonin in tissues outside the central nervous system. This could make more serotonin available in the brain while other tissues produce less of it. Outside the brain, serotonin can contribute to inflammatory processes and disturbances of gut function, among other things. Researchers are studying these differing effects as a possible link between vitamin D, mood regulation and inflammatory signaling. Whether this changes mood to a clinically relevant degree cannot be deduced from the mechanism alone.

Dopamine signaling

Vitamin D receptors are highly concentrated in the substantia nigra and the ventral tegmental area. Both brain regions are important for dopamine production. Calcitriol can promote the production of tyrosine hydroxylase, an enzyme that helps set the pace of dopamine production. Calcitriol can also protect dopamine-producing nerve cells from oxidative damage, meaning damage caused by reactive oxygen species.

Reduced dopamine signaling can go along with anhedonia: people lose pleasure and interest, feel less motivated and respond more weakly to rewards. Low vitamin D status is being discussed as a possible contributing factor. The 2023 meta-analysis linked here, however, looks at low vitamin D levels in relation to depression after a stroke. It neither directly demonstrates the dopamine mechanisms described nor shows their relevance for depression in general.

Regulation of the stress axis

The hypothalamic-pituitary-adrenal axis, or HPA axis, controls a large part of the body’s stress response. Vitamin D receptors sit both in the hypothalamus and in the adrenal glands. Calcitriol can influence how much cortisol is released and how sensitively the glucocorticoid receptors respond. Cortisol, among other hormones, acts through these receptors.

Chronic vitamin D deficiency has been linked to disturbed HPA axis regulation, higher baseline cortisol levels and impaired feedback. In this feedback loop, cortisol that is already present limits further release. When the system is disturbed, this may play a part in anxiety, irritability and lower resilience under stress. Based on its bibliographic details, however, the 2018 publication titled “Stress-Axis Regulation by Vitamin D” cannot be classified as a randomized trial.

Inflammation and nerve cell protection

Vitamin D can suppress the production of pro-inflammatory messengers such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha). Elevated levels of these messengers have been described in major depressive illness. Vitamin D also promotes the production of factors that support nerve cells. One of them is brain-derived neurotrophic factor (BDNF), a nerve growth factor. BDNF is involved in the survival of nerve cells, the adaptability of their connections and the formation of new nerve cells in the hippocampus.

The brain’s ability to adapt its connections and functions is called neuroplasticity. Reduced neuroplasticity and chronic low-grade inflammation are being studied as components of depressive illness. Vitamin D influences both processes at a biological level. That does not yet show that supplementation changes these disease mechanisms enough in people who are affected.

Dose, form and timing: what the data suggest

For supplements, vitamin D3, also called cholecalciferol, is the preferred form. It can raise and maintain blood levels of 25-OH vitamin D more effectively than vitamin D2, or ergocalciferol, which comes from plants and fungi. D3 is also the form the skin makes itself. Most of the studies discussed here that reported a mood benefit used D3.

How much vitamin D is needed to correct a deficiency depends on the starting level. The amounts below are rough figures from the publications discussed. They do not set out an individual treatment:

• For 25-OH vitamin D levels below 20 ng/mL, 2,000 to 4,000 IU a day are cited as a way to reach 30 ng/mL within 8 to 12 weeks. The 2023 study linked for this compared individualized with standardized supplementation in athletes. A dose that applies to everyone cannot be derived from it.
• For levels between 20 and 30 ng/mL, 1,000 to 2,000 IU a day are cited for maintaining supply. The linked dose comparison study looked at young healthy people. The information on how to classify it is contradictory: it is described as a non-randomized experimental study from 2024, but the reference gives 2025 as the year of publication.
• Higher doses of 5,000 to 10,000 IU a day are sometimes used under medical supervision to correct a deficiency quickly. Taking this much for longer requires monitoring to avoid an overdose. According to its title, though, the 2023 meta-analysis cited for this looks at 3,200 to 4,000 IU a day. It therefore does not establish that 5,000 to 10,000 IU is safe in general.

The tolerable upper intake level for adults is given as 4,000 IU a day. The claim that poisoning is rare with long-term intake below 10,000 IU a day does not make that amount a safety limit. The cited meta-analysis on adverse events already examines 3,200 to 4,000 IU a day. An overdose can raise blood calcium levels, a condition called hypercalcemia. Possible consequences include nausea, vomiting, weakness and impaired kidney function. Vitamin D poisoning comes from taking too much in supplement form, not from sun exposure.

Vitamin D is fat-soluble and is absorbed better with a meal that contains fat. A breakfast or dinner with some fat can therefore increase bioavailability, the share the body can actually use, compared with taking it on an empty stomach. There is little good evidence that the time of day itself makes a decisive difference to how well it works. Some practitioners recommend taking it in the morning to avoid a possible effect on melatonin production. The evidence behind this idea is not strong enough for a general recommendation, though.

Other nutrients are involved in vitamin D metabolism too. Magnesium is needed for the enzymes that convert vitamin D into its active form. A poor magnesium supply can limit the effect of supplementation and may explain why 25-OH vitamin D levels stay low despite a supplement. Vitamin K2 also helps regulate calcium metabolism, particularly the deposit of minerals in bone and processes that prevent calcium deposits in soft tissue. The studies cited do not adequately support the claim that vitamin D without added K2 generally raises the risk of vascular calcification, especially at higher doses.

Who might be more likely to benefit, and when caution is needed

Whether vitamin D might improve mood depends, among other things, on the starting level. A benefit is described more often at levels below 20 ng/mL than in people with adequate levels. Between 20 and 30 ng/mL, a limited benefit is possible. Above 30 ng/mL, an added mood benefit has not been convincingly shown. Ever-higher doses can raise the risk of an overdose. The starting level therefore helps with interpretation but does not allow a confident prediction for any one person.

A possible benefit of vitamin D is also being discussed for depression that keeps returning in winter. Less UVB reaches the skin in winter, so the skin makes less vitamin D. A supplement can partly make up for a deficiency that develops this way. The studies listed do not adequately show, however, that people with seasonal depression generally benefit more than people with non-seasonal depression. Nor can seasonal affective disorder (SAD) be explained by vitamin D deficiency alone.

As people get older, their skin makes less vitamin D under UVB exposure. Older adults therefore have a higher risk of deficiency even when they spend time in the sun. Depressive illness is also a significant issue in this population. Vitamin D supplements can treat a deficiency; a reliable reduction in the risk of depression cannot be inferred from that.

Melanin, the skin’s pigment, absorbs UVB radiation, so more heavily pigmented skin makes less vitamin D. In regions near the equator with intense UVB, this pigmentation is an adaptation to the strong radiation. At higher latitudes, less UVB is available. People with darker skin who live in northern regions therefore have a higher risk of low vitamin D levels. They may need larger amounts from a supplement to reach adequate levels. How much is actually needed cannot be determined from skin color alone, however.

Certain medications change vitamin D metabolism. Glucocorticoids such as prednisone and dexamethasone speed up the breakdown of vitamin D and reduce calcium absorption. Phenytoin and carbamazepine are anticonvulsants, drugs used against seizures. They activate liver enzymes that break down vitamin D faster. Orlistat and cholestyramine reduce fat absorption and can therefore also impair the absorption of vitamin D. With these treatments, higher vitamin D doses and more frequent monitoring may be needed. This has to be judged in each case in light of the specific medication.

The final hydroxylation step happens in the kidneys, where 25-OH vitamin D is converted into calcitriol. In chronic kidney disease, this step can be impaired. The 25-OH vitamin D level may then look normal even though too little of the active hormone form is available. In certain cases, treatment with calcitriol instead of cholecalciferol may be considered. It has to be managed carefully to avoid hypercalcemia.

Measuring vitamin D status and tracking changes

The standard marker for vitamin D status is 25-hydroxyvitamin D in blood serum. The level reflects both intake from food and the body’s own production. Its half-life, the time it takes for the amount to fall by roughly half, is about three weeks. That makes the marker a fairly stable reflection of supply over a longer period.

Under the classification used here, levels below 20 ng/mL count as deficient, levels between 20 and 30 ng/mL as insufficient, and levels above 30 ng/mL as adequate for bone health. Guidelines do not use entirely consistent cutoffs, however. Some practitioners of functional medicine aim for 40 to 60 ng/mL and describe this range as optimal for immune and nerve function. A particular mood benefit from these higher levels has not been convincingly shown.

Whether mood requires a different vitamin D level than bone health remains poorly understood. Most of the studies discussed here that reported an improvement in depressive symptoms looked at people with starting levels below 30 ng/mL. At higher starting levels, the effects were smaller. Solid evidence that levels above 50 ng/mL further improve mood is lacking. Very high levels above 100 ng/mL can be linked to unwanted effects such as hypercalcemia and a higher risk of fractures.

When a suspected deficiency is being treated deliberately, a measurement before starting establishes the baseline. A follow-up test after 8 to 12 weeks can show how the level has changed with supplementation. If it stays low, possible explanations include magnesium deficiency, impaired nutrient absorption in the gut or interactions with medications. If the level rises as expected while mood stays the same, that argues against vitamin D deficiency having been the main driver of the symptoms.

Depending on symptoms and medical history, other lab values can help with interpretation. These include high-sensitivity C-reactive protein (hsCRP) as a marker of inflammation, fasting insulin and HbA1c to assess metabolism, and cortisol and thyroid values. HbA1c reflects blood sugar exposure over a longer period. These values do not all need to be measured together for every case of low mood. Depression can rarely be explained by a shortage of a single nutrient.

What else matters when interpreting vitamin D status

Without a baseline and a follow-up measurement, it is hard to judge whether a deficiency existed when someone takes vitamin D, and whether it was corrected. The supply of other nutrients involved can also affect how vitamin D is activated. Status is usually determined by measuring 25-OH vitamin D in the blood. This test is not automatically part of every routine blood workup, however.

Symptoms also count when interpreting results, as do, depending on the situation, signs of inflammation, metabolic changes or hormonal influences. Magnesium is involved in vitamin D metabolism. Measuring it in red blood cells is mentioned in this context as one possible test. That does not create a general need for a comprehensive test package.

If symptoms persist despite months of supplementation, several explanations are possible: the absorption or activation of vitamin D might be impaired, or the symptoms might have a different cause. A higher dose on its own does not answer the question of what the cause is.

Frequently asked questions

How does vitamin D affect mood and mental health?

Vitamin D receptors are found in the prefrontal cortex, the hippocampus, the hypothalamus and the substantia nigra, among other places. These brain regions are involved in impulse control, mood, memory and dopamine production. When the active hormone form, calcitriol, binds to these receptors, it can regulate genes involved in making neurotransmitters, protecting nerve cells and inflammatory processes.

One area of research, for example, is how vitamin D regulates tryptophan hydroxylase 2 (TPH2). This enzyme helps set the pace of serotonin production in the brain. Another mechanism involves tyrosine hydroxylase, which takes part in making dopamine. A poor vitamin D supply could impair these processes. That alone, however, neither explains what caused a depression nor allows a reliable treatment effect to be inferred.

What is the link between vitamin D deficiency and depression?

A 2019 meta-analysis of 61 observational studies reported statistically significantly higher rates of depression in people with vitamin D deficiency than in people with adequate levels. The association held after accounting for physical activity, sun exposure and mental health at baseline. The full reference for this meta-analysis is missing.

Observational studies cannot prove that the deficiency causes the depression. Similar findings in several groups, and possible effects on serotonin, dopamine and the HPA stress axis, make a contribution from vitamin D biologically plausible. Levels below 30 ng/mL are commonly described and can go unnoticed without a specific test. Under the classification used here, though, only a level below 20 ng/mL counts as deficient. So not every level below 30 ng/mL falls into that category.

What do clinical studies say about vitamin D for depression?

The results vary. One possible explanation is the starting vitamin D level. A 2014 meta-analysis reported a moderate improvement in depressive symptoms compared with placebo, rated as clinically relevant, especially at levels below 20 ng/mL. A 2018 study in women with depression and type 2 diabetes is described as showing a significant improvement in symptoms after 50,000 IU per week for eight weeks. Neither of these can be clearly matched to an entry in the bibliography.

In the large VITAL-DEP trial, the average starting level was 30 ng/mL. Supplementation did not lead to significantly fewer new cases of depression. These differences fit with the assumption that correcting a deficiency is more likely to help than extra supplementation when levels are already adequate. Whether this pattern applies to any particular person cannot be reliably predicted from it.

How does vitamin D affect the production of serotonin and dopamine?

Vitamin D can regulate TPH2 in the brain. This enzyme controls a step that helps set the pace of serotonin production. Inhibition of TPH1 in tissues outside the brain has also been described. Vitamin D might therefore influence serotonin production in the central nervous system differently from the rest of the body.

Calcitriol can also promote tyrosine hydroxylase, which is involved in dopamine production in the substantia nigra and the ventral tegmental area. Protective effects on dopamine-producing nerve cells against oxidative damage have been described too. Low vitamin D levels have been linked to anhedonia (the loss of pleasure and interest), low motivation and a blunted response to rewards. These symptoms can also occur with reduced dopamine signaling. The associations do not prove, however, that vitamin D deficiency is the cause in any individual case.

What vitamin D level is optimal for mood and mental health?

A separate optimal target level for mood is not adequately supported. Here, a level above 30 ng/mL is used as a guide for adequate supply for bone health. Whether most guidelines use exactly this cutoff cannot be confirmed from the literature cited, however.

Studies that reported a mood benefit mostly looked at people with starting levels below 30 ng/mL. At higher starting levels, the reported effects were smaller. In functional medicine, 40 to 60 ng/mL is often the target and is described as optimal for neurological and immune function. There is only limited solid evidence for a particular mood benefit in this range. Levels above 100 ng/mL can be associated with risks such as hypercalcemia and a higher risk of fractures.

What vitamin D dose might be considered for deficiency and low mood?

For 25-OH vitamin D levels below 20 ng/mL, 2,000 to 4,000 IU of vitamin D3 a day are cited as a way to reach 30 ng/mL within 8 to 12 weeks. For levels between 20 and 30 ng/mL, 1,000 to 2,000 IU a day are given for maintaining supply. These amounts guarantee neither a particular blood level nor a better mood. They are not an individual treatment recommendation.

Doses of 5,000 to 10,000 IU a day are sometimes used under medical supervision to correct a deficiency quickly. Anyone taking that much for longer needs monitoring. The tolerable upper intake level for adults is given as 4,000 IU a day.

Vitamin D3, also called cholecalciferol, raises blood levels more effectively and keeps them up better than D2. It is absorbed better with a meal that contains fat.

Why does seasonal depression get worse in winter?

UVB exposure drops in winter. As a result, the skin makes fewer vitamin D precursors, and the 25-OH vitamin D level can fall over the course of the winter months. Whether this contributes to seasonal mood changes through effects on serotonin and dopamine regulation is under discussion.

Seasonal affective disorder (SAD) can bring low mood, lack of energy and hypersomnia. Hypersomnia means an increased need for sleep or sleeping too much. A falling vitamin D level alone does not explain these symptoms. Taking vitamin D can correct a deficiency that develops seasonally. The studies cited do not show, however, that people with winter depression therefore reliably benefit more than people with non-seasonal depression.

How can vitamin D status be checked and tracked when an effect on mood is suspected?

The standard marker is 25-hydroxyvitamin D in blood serum. With a half-life of roughly three weeks, it gives a fairly stable picture of longer-term supply. If a suspected deficiency is to be treated deliberately, the baseline level can be measured before starting. A repeat measurement after 8 to 12 weeks shows how the level has changed with supplementation.

If the expected rise does not happen, possible reasons include magnesium deficiency, impaired absorption in the gut or medications that speed up the breakdown of vitamin D. These medications include certain corticosteroids and anticonvulsants.

Depending on symptoms and medical history, other lab values can help: hsCRP as a marker of inflammation, fasting insulin and HbA1c as metabolic markers, and cortisol and thyroid values. Such an extended lab panel is not needed for every case of low mood. A single nutrient deficiency rarely explains depression completely.

References

1. Jorde R, Kubiak J (2018). No improvement in depressive symptoms by vitamin D supplementation: results from a randomised controlled trial. Journal of nutritional science, 7, e30. https://doi.org/10.1017/jns.2018.19. PubMed.

2. Okereke OI, Reynolds CF, Mischoulon D, Chang G, Vyas CM, Cook NR, Weinberg A, Bubes V, Copeland T, Friedenberg G, Lee IM, Buring JE, Manson JE (2020). Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA, 324(5), 471-480. https://doi.org/10.1001/jama.2020.10224. PubMed.

3. Park Y, Ah YM, Yu YM (2023). Vitamin D supplementation for depression in older adults: a meta-analysis of randomized controlled trials. Frontiers in nutrition, 10, 1169436. https://doi.org/10.3389/fnut.2023.1169436. PubMed.

4. Hung KC, Wu JY, Illias AM, Chiu CC, Chang YJ, Liao SW, Wang KF, Chen IW, Sun CK (2023). Association of a low vitamin D status with risk of post-stroke depression: A meta-analysis and systematic review. Frontiers in nutrition, 10, 1142035. https://doi.org/10.3389/fnut.2023.1142035. PubMed.

5. Rolf L, Damoiseaux J, Huitinga I, Kimenai D, van den Ouweland J, Hupperts R, Smolders J (2018). Stress-Axis Regulation by Vitamin D. Frontiers in neurology, 9, 263. https://doi.org/10.3389/fneur.2018.00263. PubMed.

6. Tuma C, Schick A, Pommerening N, Braun H, Thevis M (2023). Effects of an Individualized vs. Standardized Vitamin D Supplementation on the 25(OH)D Level in Athletes. Nutrients, 15(22). https://doi.org/10.3390/nu15224747. PubMed.

7. Kralova M, Jirasko M, Dedeckova E, Hatakova H, Broz P, Simanek V, Slouka D, Pecen L, Kucera R (2025). Comparison of Vitamin D3 Supplementation Doses of 1,000, 2,000, 4,000 and 8,000 IU in Young Healthy Individuals. In vivo (Athens, Greece), 39(1), 452-458. https://doi.org/10.21873/invivo.13848. PubMed.

8. Zittermann A, Trummer C, Theiler-Schwetz V, Pilz S (2023). Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials. European journal of nutrition, 62(4), 1833-1844. https://doi.org/10.1007/s00394-023-03124-w. PubMed.